Eleutheroside E (Synonyms: Syringin E) |
カタログ番号GN10300
One-Click Copy Product Info
|
Eleutheroside E (EE)はエゾウコギの主な活性成分であり、抗疲労、神経保護と免疫調節作用を持っている。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 39432-56-9
Sample solution is provided at 25 µL, 10mM.
Eleutheroside E (EE)はエゾウコギの主な活性成分であり、抗疲労、神経保護と免疫調節作用を持っている[1]。
体外で、Eleutheroside E (100、300と500μM；48時間)は、ミトコンドリアん膜電位を増やし、細胞内活性酸素種（ROS）のレベルを減らすことで、1-メチル-4-フェニル-1,2,3,6-テトラヒドロピリジン(MPTP)誘発のPC-12細胞のアポトーシスを改善できる[2]。Eleutheroside E (25μM；72時間)は、子宮頸癌（CC）細胞で、アポトーシスを促進し、細胞の生存率を阻害した[3]。Eleutheroside E (30, 60と100mM；12時間)は、低酸素症-再酸素化(H/R)損傷に誘発された心筋細胞のアポトーシスを軽減した[4]。
体内で、Eleutheroside E (50と100 mg/kg；3日間；腹腔内)の事前処理は、高地肺水腫(HAPE)の病理的な表現（例えば肺胞出血、肺胞壁の肥厚、炎症細胞浸潤、肺胞と間質の浮腫など）を改善でき、効果は用量と正の関係にある[1]。Eleutheroside E (50 mg/kg/日；4週間)の添加は、マウスの海馬体で、放射線誘発性認知障害、ニューロン形態と超微細構造の損傷を予防できる[5]。Eleutheroside E (10mg/kg；20日間；経口)はラットで、5-ヒドロキシトリプタミン受容体2C (Htr2c)-依存的に、脳虚血再潅流の損傷を軽減する[6]。
References:
[1] Shen Z, Huang D, Jia N, Zhao S, Pei C, Wang Y, Wu Y, Wang X, Shi S, Wang F, He Y, Wang Z. Protective effects of Eleutheroside E against high-altitude pulmonary edema by inhibiting NLRP3 inflammasome-mediated pyroptosis. Biomed Pharmacother. 2023 Nov;167:115607.
[2] Yao Y, Liao C, Qiu H, Liang L, Zheng W, Wu L, Meng F. Effect of Eleutheroside E on an MPTP-Induced Parkinson's Disease Cell Model and Its Mechanism. Molecules. 2023 Apr 29;28(9):3820.
[3] Cai Y, Zhang J, Xin T, Xu S, Liu X, Gao Y, Huang H. Eleutheroside E functions as anti-cervical cancer drug by inhibiting the phosphatidylinositol 3-kinase pathway and reprogramming the metabolic responses. J Pharm Pharmacol. 2022 Sep 1;74(9):1251-1260.
[4] Wang S, Yang X. Eleutheroside E decreases oxidative stress and NF-κB activation and reprograms the metabolic response against hypoxia-reoxygenation injury in H9c2 cells. Int Immunopharmacol. 2020 Jul;84:106513.
[5] Song C, Duan F, Ju T, Qin Y, Zeng D, Shan S, Shi Y, Zhang Y, Lu W. Eleutheroside E supplementation prevents radiation-induced cognitive impairment and activates PKA signaling via gut microbiota. Commun Biol. 2022 Jul 8;5(1):680.
[6] Liu Z, Gao W, Xu Y. Eleutheroside E alleviates cerebral ischemia-reperfusion injury in a 5-hydroxytryptamine receptor 2C (Htr2c)-dependent manner in rats. Bioengineered. 2022 May;13(5):11718-11731.
| 細胞実験[1]: | |
細胞株 | HelaとSiHa |
準備方法 | 0と25µM Eleutheroside Eを投与した後、HelaとSiHa細胞を採取し、リン酸緩衝の生理食塩水（PBS）で洗浄し、0.5mlの結合緩衝液で再懸濁し、室温で5µlのヨウ化プロピジウム(PI)と5µlのAnnexin V/FITCを15分間染色した。細胞のアポトーシスを、CellQuestソフトウェアを使い、FACScanフローサイトメトリーで分析した。 |
反応条件 | 25μM；72時間 |
アプリケーション | Eleutheroside Eは、子宮頸癌（CC）細胞で、アポトーシスを促進し、細胞の生存率を阻害した。 |
| 動物実験 [2]: | |
動物モデル | 雄のSprague-Dawleyラット；100–110g；4–5週間 |
準備方法 | 計42匹のラットをランダムに下記の6つのグループ（n = 7）に分けた：(1)模擬手術、(2) Eleutheroside E, (3) HAPE, (4) Eleutheroside E 50mg/kg + HAPE, (5) Eleutheroside E 100mg/kg + HAPE、(6) Eleutheroside E 100mg/kg + Nig 4mg/kg + HAPE。 模擬手術とHAPE群のマウスには正常な生理食塩水を腹腔内注射し、その他の4つのグループには、対応する用量のEleutheroside Eを3日間腹腔内注射した。NLRP3の活性剤としてのNigを使い、HAPEでNLRP3媒介のピロプトーシスに対するEleutheroside Eの効果を検証した。（6）グループのラットに、Eleutheroside Eの最後の投与の30分前に、Nigを腹腔内注射した。 |
投与形態 | 50と100mg/マウス；3日間；腹腔内注射 |
アプリケーション | Eleutheroside E (50と100 mg/kg；3日間；腹腔内)の事前処理は、高地肺水腫(HAPE)の病理的な表現（例えば肺胞出血、肺胞壁の肥厚、炎症細胞浸潤、肺胞と間質の浮腫など）を改善でき、効果は用量と正の関係にある。 |
References: | |
| Cas No. | 39432-56-9 | SDF | |
| 同義語 | Syringin E | ||
| Chemical Name | (2R,3S,4R,5R,6S)-2-[4-[6-[3,5-dimethoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2,6-dimethoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| Canonical SMILES | COC1=CC(=CC(=C1OC2C(C(C(C(O2)CO)O)O)O)OC)C3C4COC(C4CO3)C5=CC(=C(C(=C5)OC)OC6C(C(C(C(O6)CO)O)O)O)OC | ||
| Formula | C34H46O18 | M.Wt | 742.72 |
| 溶解度 | ≥ 26.2mg/mL in DMSO | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3464 mL | 6.732 mL | 13.464 mL |
| 5 mM | 269.3 μL | 1.3464 mL | 2.6928 mL |
| 10 mM | 134.6 μL | 673.2 μL | 1.3464 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)